LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $68,102 | +250.6% | 68,286 | +420.4% | 0.00% | – |
| Q1 2024 | $19,422 | -94.2% | 13,123 | -94.1% | 0.00% | -100.0% |
| Q1 2023 | $332,919 | +106.8% | 221,946 | +61.3% | 0.00% | 0.0% |
| Q4 2022 | $160,955 | +37.6% | 137,568 | +33.1% | 0.00% | 0.0% |
| Q3 2022 | $117,000 | -17.6% | 103,322 | +14.9% | 0.00% | 0.0% |
| Q2 2022 | $142,000 | -68.4% | 89,960 | -53.0% | 0.00% | -85.7% |
| Q1 2021 | $450,000 | +36.0% | 191,483 | +1.9% | 0.01% | +40.0% |
| Q4 2020 | $331,000 | +263.7% | 187,964 | +94.4% | 0.01% | +400.0% |
| Q3 2020 | $91,000 | -22.9% | 96,704 | -28.4% | 0.00% | -50.0% |
| Q2 2020 | $118,000 | – | 135,138 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
| Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
| Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
| Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
| DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
| CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
| Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
| One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |